70.45 -0.10 (-0.14%)
After hours: 5:27PM EST
|Bid||70.13 x 800|
|Ask||70.97 x 800|
|Day's Range||70.17 - 71.71|
|52 Week Range||64.27 - 89.54|
|Beta (3Y Monthly)||1.39|
|PE Ratio (TTM)||58.55|
|Earnings Date||Feb 4, 2019 - Feb 8, 2019|
|Forward Dividend & Yield||2.28 (3.17%)|
|1y Target Est||86.15|
Consider Gilead Sciences (GILD) and Celgene (CELG) for example. At recent prices of $70 and $75, they traded at market values that aren’t too far above the value of their operating businesses, according to discounted cash flow analysis by Jefferies biotech analyst Michael Yee and his team. Then add if they fall back to their “free pipeline” stock prices.
With the earnings season coming to an end, data presentations on key drugs and candidates hog the limelight this week.
Express Scripts Holding Co on Tuesday announced a new drug reimbursement list with lower U.S. prices for brand-name medications, as a way to encourage drugmakers to move away from paying rebates after a prescription is filled. The manager of prescription drug benefits for large corporate employers and government health plans said its new National Preferred Flex Formulary will be available as of Jan. 1 to all clients. Drug rebates have come under fire from the Trump Administration and consumer groups as patients find themselves paying much higher insurance co-payments and deductibles tied to a drug's sticker price.
In November 2018, of the total ten analysts covering Nektar Therapeutics (NKTR), eight analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Nektar Therapeutics stock is 1.8 with a target price of $88.5, implying an upside potential of 160.1% over Nektar Therapeutics’ trading price of $34.03 on November 10.
Nine companies have majority ‘buy’ ratings, with upside potential of as much as 123%, according to analysts.
Gilead Sciences, Inc. (GILD) today announced that treatment with GS-9674, an investigational, selective, nonsteroidal farnesoid X receptor (FXR) agonist, led to significant improvements in liver biochemistry and markers of cholestasis in patients with primary sclerosing cholangitis (PSC). PSC is a rare, chronic condition that causes the network of ducts that drain bile from the liver to become inflamed and scarred over time. Progressive damage to the bile ducts in patients with PSC can lead to cirrhosis, liver failure, and cholangiocarcinoma (cancer of the bile ducts).
– Data Demonstrate Sofosbuvir-Based Regimens Achieve High Cure Rates in Hepatitis C Patient Populations with Unmet Need –
Gilead Sciences, Inc. (GILD) today announced new data from the company’s clinical development program for advanced fibrosis due to nonalcoholic steatohepatitis (NASH). Data presented support the ongoing development of the company’s investigational compounds, evaluate the utility of noninvasive tests for the identification of patients with advanced fibrosis, and demonstrate the significant burden of disease in affected patients. In this study, 140 NASH patients were treated with GS-9674 100 mg, GS-9674 30 mg or placebo orally once daily for 24 weeks.
Gilead Sciences Inc (NASDAQ:GILD), a large-cap worth US$91.0b, comes to mind for investors seeking a strong and reliable stock investment. Market participants who are conscious of risk tend to search Read More...
This company wants to make treating an irregular heartbeat as easy as reaching into your backpack, and it's just raised cash to take the first part of that vision into a mid-stage clinical trial.
After decades of anemic housing production, Belmont is luring more housing to its El Camino Real corridor including a new proposal for 250 apartments.
In November, among the 28 analysts covering Gilead Sciences (GILD), six recommended a “strong buy,” ten recommended a “buy,” and 12 recommended a “hold.” The mean rating for Gilead Sciences stock is 2.21 with a target price of $86.15, which implies an upside potential of 22.5% over Gilead Sciences’ closing price of $70.31 on November 1.
Gilead Sciences’ (GILD) total HIV sales got a boost from the US market. The HIV product sales in the United States increased from $2.52 billion in the third quarter of 2017 to $3.0 billion in the third quarter. The HIV product sales in Europe decreased from $656.0 million in the third quarter of 2017 to $584.0 million in the third quarter. The sales in other international markets decreased from $156.0 million in the third quarter of 2017 to $138.0 million in the third quarter. Gilead Sciences’ Biktarvy generated US sales of $375. ...
In a note to clients on Thursday, Morgan Stanley analysts downplayed the risk of an announcement by UnitedHealth Group Inc. ( UNH), which investors view as potentially eating into Gilead's revenues for its pricey drug treatments, as outlined by Barron's. Shares of Gilead plunged as much as 6% on Wednesday following news that UnitedHealth is launching a rewards program called My Scripts Reward, which promotes the use of low-cost therapies. Morgan Stanley analyst Matthew Harrison, who rates shares of the Foster City, Calif.-based biotechnology company at equal weight, noted a handful of issues with UnitedHealth's announcement.
GILD has been trying to turn itself around, but few, including Jim Cramer, see that turn coming any time soon. In this daily bar chart of GILD, below, has been struggling to mount a sustained rally. Is this the start of a new downtrend or just part of a longer base-building process?
Gilead Sciences’ (GILD) cost of goods sold increased marginally from $1.03 billion in the third quarter of 2017 to $1.09 billion in the third quarter.
Gilead Sciences’ (GILD) interest expense decreased from $291.0 million in the third quarter of 2017 to $264.0 million in the third quarter. The company’s income tax provision also decreased from $959.0 million in the third quarter of 2017 to $565.0 million in the third quarter.
For Gilead Sciences’ (GILD) Biktarvy, declining revenues and stock price movements have kept investors interested in the stock. In this series, we’ll explore Gilead Sciences’ financials, the performance of the company’s geographic segments, analysts’ recommendations for the stock, and the company’s valuation metrics.
bluebird (BLUE) incurs narrower-than-expected Q3 loss on account of higher collaboration revenues. The pipeline progress looks encouraging.
The Decatur-based Task Force for Global Health is becoming ground zero for the global elimination of hepatitis B and C.
Merck & Co.’s (MRK) Zepatier reported revenues of $104 million in the third quarter compared to $468 million in the third quarter of 2017, reflecting a ~78% YoY (year-over-year) decline and an 8% sequential decline.